This eBook from ACROBiosystems looks at the connected landscape of metabolic diseases - including type 1 and type 2 diabetes, obesity, and metabolic associated steatotic liver disease (MASLD) - and how therapeutic strategies are evolving to address them.
It covers key mechanisms like insulin resistance, chronic inflammation, and metabolic imbalance, and highlights emerging drug targets and multi-mechanism approaches shaping the next wave of metabolic treatments.
Download the eBook to explore ACROBiosystems’ full portfolio of recombinant proteins, antibodies, functional cell lines, assay kits, organoid solutions, and expert analytical services that are designed to accelerate discovery, streamline development, and support translation across the metabolic disease drug development pipeline.
About ACROBiosystems
ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Their mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. They supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, ACROBiosystems delivers solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. ACROBiosystems empowers scientists and engineers dedicated to innovation to simplify and accelerate the development of new, better, and more affordable medicine.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.